Chemkart India Ltd. · BSE:CHEMKART
Chemkart India — H2 FY26 Earnings Presentation
39 slides from Chemkart India's earnings presentation, May 18, 2026
Slide 1: Investor Presentation Submission Letter to BSE
CHEMKART INDIA LIMITED + \hemkart® CIN-L51220MH2020PLC338631 U 403/404 K.L. Accolade, 4*" Floor, Above Captain Gym, Nr. RK. Hospital Ingredients, Simplified. Santacruz (E), MUMBAI 400055 Email Id: [email protected] | Customer Care: +91 9136383828 Chemkart India Ltd 18t May 2026 To, BSE Limited
Slide 2: Chemkart India Ltd Investor Presentation - May 2026
Chemkart India Ltd Investor Presentation - May 2026
Slide 3: Disclaimer
Disclaimer This presentation and the accompanying slides (the “Presentation”), which have been prepared by Chemkart India Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securit
Slide 4: Company Overview
Company Overview Industry Overview Strategic Overview Half-Yearly Financial Performance Historical Financial Performance Investment Rationale
Slide 5: The Foundation of Our Future
The Foundation of Our Future Mission Vision To drive growth and To be a global leader in excellence in food and end-to-end CDMO health ingredients solutions and trusted through quality sourcing, distribution of food, trusted partnerships, and health, and specialty innovative, sustainable ingredients
Slide 6: Company Snapshot
Company Snapshot 10+ Product Categories Certifications: ISO 9001:2015 | FSSAI | ETC | 150+ Ingredients Pan-India Distribution Network Revenue: 26.9% 500+ Trusted Clients (2 Year CAGR) EBITDA: 17.6% PAT: 19.6% 15% 30K Sq.Ft Warehouse (FY26) ROE: ROCE: 21% Investor Presentation – May 2026 5
Slide 7: About Chemkart
About Chemkart Chemkart India Limited, established in March 2015 and headquartered in Mumbai, is a B2B supplier of high-quality raw ingredients used in the manufacturing of nutritional, sports, and health supplements. The company serves a broad spectrum of manufacturers across India, offering a dive
Slide 8: Chemkart's Present Journey
Chemkart’s Present Journey • Launched Vinstar Biotech as a subsidiary to diversify and broaden business horizons. • Established presence in SEZ with a dedicated sales unit to scale operations. Established EZRM as a Subsidiary to tap into new market segments & strengthen Chemkart presence. 2025 Chemk
Slide 9: Vision 2030: Global Biotechnology Leader
Vision 2030: Global Biotechnology Leader • Commissioning of EZRM SEZ Facility – India’s first nutraceutical-focused SEZ hub • Full-service CDMO offerings: • Scale-up of novel technologies: liposomal, custom molecules → finished microencapsulation, nanoemulsion, dosage forms 2025 beadlets • Establish
Slide 10: Transitioning Into Manufacturing
Transitioning Into Manufacturing Chemkart India Limited (CIL) announced the commencement of full-scale construction of a greenfield facility at its wholly owned subsidiary, Easy Raw Materials Pvt. Ltd. (EZRM), located in the JNPT Special Economic Zone (SEZ), Maharashtra. This next-generation nutrace
Slide 11: Our upcoming facility JNPA
Our upcoming facility JNPA Projected Outlay for the Manufacturing Facility Investor Presentation – May 2026 10
Slide 12: Updates On Manufacturing Unit
Updates On Manufacturing Unit Project Progress Updates Civil foundation and plinth-level development activities are progressing steadily in a phased manner across the manufacturing facility. Reinforcement and casting work for pile caps in both utility and core manufacturing zones are actively under
Slide 13: Showcasing Our Strength: Products & Partnerships
Showcasing Our Strength: Products & Partnerships Our Leading Product Portfolio Clientele at a Glance Glycine Creatine Monohydrate 200 Mesh Inositol BCAA 2:1:1 (Leucine, Isoleucine, Valine) L-Glutamine L-Carnitine N-Acetyl L-Cysteine (NAC) Taurine L-Glutathione (Reduced) Whey Protein Concentrate 80%
Slide 14: Domestic Stronghold with Emerging Global Reach
Domestic Stronghold with Emerging Global Reach Germany Slovakia Switzerland Turkey Portugal South Nepal Korea U.A.E Saudi Arabia Bhiwandi Geographic Revenue Breakup Sri Lanka 1.3% 98.7% New Zealand Export Domestic Warehousing facility in Bhiwandi, Maharashtra spans 28,259 sq. ft. across three floors
Slide 15: Robust Storage & Processing Capabilities
Robust Storage & Processing Capabilities 150+ Ingredients 30000 Sq.ft Warehouse 50+ 1.5MT/Day Blending Employee 1.8MT/Day Capacity Grinding Strength Capacity Investor Presentation – May 2026 14
Slide 16: Our Group Companies
Our Group Companies Vinstar Biotech Limited Easy Raw Materials Pvt. Ltd Supports science-led platforms in Focused on the manufacturing & biotech, life sciences, chemicals, and export of high-quality nutraceutical R&D-driven innovation. Its and wellness products, driven by involvement aligns with Che
Slide 17: Leadership Behind Chemkart
Leadership Behind Chemkart Ankit Shailesh Mehta Parul Shailesh Mehta Shailesh Vinodrai Mehta Chairman & Managing Director Promoter & Executive Director Promoter & Executive Director He holds a Bachelor's degree in With 9 years of experience in the A commerce graduate from the (Chemical Engineering)
Slide 18: Certifications
Certifications ISO 9001:2015 Certified FSSAI License ISO 22000:2018 Certified HALAL Certified KOSHER Certified Investor Presentation – May 2026 17
Slide 19: Industry Overview
Company Overview Industry Overview Strategic Overview Half-Yearly Financial Performance Historical Financial Performance Investment Rationale
Slide 20: Powering India's $76 Billion Health Revolution
Powering India’s $76 Billion Health Revolution India’s nutraceutical market is growing at 10% CAGR, projected to reach USD 76 billion by 2033, backed by rising health-conscious consumer spending. A wellness-focused middle class and expanding elderly population are driving sustained demand for functi
Slide 21: Trends Fueling the Next Wave of Nutraceutical Growth
Trends Fueling the Next Wave of Nutraceutical Growth India’s 1,700+ medicinal plants are fueling demand for standardized 01 herbs like turmeric, tulsi, and ashwagandha. Backed by modern AYURVEDA 2.0 extraction and global clinical validation, Ayurvedic blends are gaining popularity, with growing expo
Slide 22: Strategic Overview
Company Overview Industry Overview Strategic Overview Half-Yearly Financial Performance Historical Financial Performance Investment Rationale
Slide 23: Present Edge & Future Focus
Present Edge & Future Focus: Strategic Advantages Path Ahead Experienced Team: Product Expansion: Strong leadership with deep industry knowledge. Our new manufacturing facility marks strategic entry into CDMO, expanding capabilities and offerings. Cost-Efficient Operations: Vertical Integration: Lea
Slide 24: Driving Growth Through Strategic Outreach
Driving Growth Through Strategic Outreach Strengthening Digital B2B Presence By leveraging online B2B platforms, we’ve expanded nationwide visibility, generated high-quality leads, and strengthened our presence across chemical and nutraceutical industries. Customer-Centric Market Alignment Our sales
Slide 25: Half-Yearly Financial Performance
Company Overview Industry Overview Strategic Overview Half-Yearly Financial Performance Historical Financial Performance Investment Rationale
Slide 26: Management Commentary
Management Commentary In FY26, the Company delivered a measured performance amid a challenging global operating environment, impacted by supply chain disruptions, pricing corrections across key product categories, and uncertainties surrounding US tariff policies, which affected demand from certain e
Slide 27: Key Financial Highlights
Key Financial Highlights Revenue (INR Lacs) EBITDA (INR Lacs) PAT (INR Lacs) 23.8% 10.9% 6.8.% 11,160.4 1,402.1 1,264.2 950.3 9,015.2 889.6 H2 FY25 H2 FY26 H2 FY25 H2 FY26 H2 FY25 H2 FY26 EBITDA Margins (In %) PAT Margins (In %) 14.0% 9.9% 8.5% 12.6% H2 FY25 H2 FY26 H2 FY25 H2 FY26 Investor Presenta
Slide 28: Consolidated Income Statement
Consolidated Income Statement Particulars (Rs. Lacs) H2 FY26 H2 FY25 Y-o-Y H1 FY26 H-o-H FY26 FY25 Y-o-Y Revenue from Operations 11,160.4 9,015.2 23.8% 10,322.6 8.1% 21,482.9 20,327.9 5.7% Cost of Materials Consumed 141.1 434.8 1,005.2 1,146.3 748.6 Purchase of Stock in Trade 10,364.9 7,490.7 7,494.
Slide 29: Standalone Income Statement
Standalone Income Statement Particulars (Rs. Lacs) H2 FY26 H2 FY25 Y-o-Y H1 FY26 H-o-H FY26 FY25 Y-o-Y Revenue from Operations 11,050.8 9,015.2 22.6% 10,208.7 8.2% 21,259.5 20,327.9 4.6% Cost of Materials Consumed 141.1 434.8 1,005.2 1,146.3 748.6 Purchase of Stock in Trade 10,270.6 7,490.7 7,382.6
Slide 30: Consolidated Balance Sheet
Consolidated Balance Sheet Assets (Rs. Lacs) Mar-26 Mar-25 Equity And Liabilities (Rs. Lacs) Mar-26 Mar-25 Non ‐ Current Assets Shareholders Funds a)Property, plant and equipment and (a) Equity share capital 1,209.9 949.9 Intangible Assets (b)Reserves and Surplus 11,763.1 4,378.7 i)Property, plant a
Slide 31: Standalone Balance Sheet
Standalone Balance Sheet Assets (Rs. Lacs) Mar-26 Mar-25 Equity And Liabilities (Rs. Lacs) Mar-26 Mar-25 Non ‐ Current Assets Shareholders Funds a)Property, plant and equipment and (a) Equity share capital 1,209.9 949.9 Intangible Assets (b)Reserves and Surplus 11,895.9 4,400.9 i)Property, plant and
Slide 32: Consolidated Cashflow Statement
Consolidated Cashflow Statement Particulars (Rs. Lacs) Mar-26 Mar-25 Cash Flow from Operating Activities Profit before Tax 2,688.9 3,247.5 Adjustment for Non-Operating Items 224.9 224.9 Operating Profit before Working Capital Changes 2,913.8 3,472.5 Changes in Working Capital -2,418.1 -2,491.8 Cash
Slide 33: Standalone Cashflow Statement
Standalone Cashflow Statement Particulars (Rs. Lacs) Mar-26 Mar-25 Cash Flow from Operating Activities Profit before Tax 2,800.6 3,271.1 Adjustment for Non-Operating Items 178.5 215.9 Operating Profit before Working Capital Changes 2,979.1 3,487.0 Changes in Working Capital -2,602.8 -2,901.8 Cash Ge
Slide 34: Historical Financial Performance
Company Overview Industry Overview Strategic Overview Half-Yearly Financial Performance Historical Financial Performance Investment Rationale
Slide 35: Segment-Wise Revenue Contribution
Segment-Wise Revenue Contribution FY24 FY25 FY26 1.7% 2.3% 2.7% 2.3% 1.8% 6.8% 46.8% 44.4% 30.9% 24.9% 33.2% 48.5% 2.3% 11.4% 2.7% 11.9% 3.0% 1.5% 3.2% 12.4% 0.9% 2.0% 0.9% 1.6% Amino Acids Health Supplement Herbal Extract Nucleotide Protein Sports Nutrition Vitamin Other Product Category FY24 FY25
Slide 36: Key Financial Highlights
Key Financial Highlights Revenue (INR Lacs) EBITDA (INR Lacs) and EBITDA Margin (%) PAT (INR Lacs) and PAT Margin (%) 2,453.3 21,482.9 3,287.1 20,327.9 2,817.7 1,965.5 13,137.8 13,202.7 2,091.2 1,451.8 12.1% 15.8% 16.2% 766.0 11.0% 1,105.0 13.1% 9.1% 5.8% 8.4% FY23 FY24 FY25 FY26 FY23 FY24 FY25 FY26
Slide 37: Investment Rationale
Company Overview Industry Overview Strategic Overview Half-Yearly Financial Performance Historical Financial Performance Investment Rationale
Slide 38: Investment Rationale
Investment Rationale Profitable Product Mix Strong Customer Network Greenfield Expansion Specialty chemicals Focused on B2B, Investing in EZRM’s and nutraceuticals building trusted greenfield manufacturing across pharma, relationships to expand project to improve personal care, and B2B customers and
Slide 39: Thank You!
Company Chemkart India Limited CIN: L51220MH2020PLC338631 Email ID: [email protected] Tel: + 91 9136383828 Website: www.chemkart.com Thank You! Investor Relations Partner X-B4 Advisory LLP Rasika Sawant / Aagam Shah Tel: +91 95944 57518 / +91 8850166932 Email ID: [email protected] / [email protected]